Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

Bellerophon Therapeutics logo

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

Advanced Chart

Key Stats

Today's Range
$0.0120
$0.0126
50-Day Range
$0.01
$0.06
52-Week Range
$0.0116
$0.0190
Volume
7,027 shs
Average Volume
18,907 shs
Market Capitalization
$146.80 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Stock News Headlines

Bellerophon Therapeutics Inc. (BLPH) Charts
A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
Bellerophon Therapeutics, Inc. (BLPH)
Bellerophon Therapeutics Inc (BLPH)
Bellerophon Therapeutics Inc BLPH
See More Headlines

BLPH Stock Analysis - Frequently Asked Questions

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

Shares of Bellerophon Therapeutics reverse split before market open on Monday, February 10th 2020.The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Bellerophon Therapeutics (BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), iBio (IBIO) and Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2023
Today
7/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BLPH
CIK
1600132
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$5.64 million
Price / Sales
0.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.27 per share
Price / Book
0.04

Miscellaneous

Outstanding Shares
12,233,000
Free Float
11,597,000
Market Cap
$146.80 thousand
Optionable
No Data
Beta
0.74

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:BLPH) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners